AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus

por Chakka, Srita, Krain, Rebecca, Ahmed, Sarah, Concha, Josef Symon S., Werth, Victoria P.
Publicado 2021

AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus

por Chakka, Srita, Krain, Rebecca, Ahmed, Sarah, Concha, Josef Symon S., Feng, Rui, Werth, Victoria P.
Publicado 2021

AB003. Increased CD69+ tissue-resident memory T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials

por Zeidi, Majid, Chen, Kristen L., Desai, Krisha, Kim, Hee Joo, Chakka, Srita, Lim, Rachel, Werth, Victoria P.
Publicado 2021

The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review

por Chakka, Srita, Krain, Rebecca L., Concha, Josef Symon S., Chong, Benjamin F., Merola, Joseph F., Werth, Victoria P.
Publicado 2021

Cutaneous lupus concerns from the patient perspective: a qualitative study

por Yan, Daisy, Zamalin, Danielle, Chakka, Srita, Krain, Rebecca, Concha, Josef, Feng, Rui, Ahmed, Sarah, Okawa, Joyce, Werth, Victoria P
Publicado 2021